Citations

Showing 10 of 108094 citations.

Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer
Kohale, Ishwar N. , Yu, Jia , Zhuang, Yongxian , Fan, Xiaoyang , Reddy, Raven J. , Carter, Jodi M. , Goetz, Matthew P. , Wang, Liewei , White, Forest M. , Sinnwell, Jason, White, Forest M , Goetz, Matthew P , Carter, Jodi , Sinnwell, Jason P. , Kalari, Krishna R. , Boughey, Judy C.

Mayo Clinic

Cancers | August 30, 2022 | Volume: 14 | Issue: 17 | Pages: 4220

10.3390/cancers14174220 | PMID 36077757 Get It

Neoadjuvant chemotherapy (NAC) remains the cornerstone of the treatment for triple negative breast cancer (TNBC), with the goal of complete eradication of disease. However, for patients with residual disease after NAC, recurrence and mortality rates are high and the identification of novel therapeutic targets is urgently needed. We quantified tyrosine phosphorylation (pTyr)-mediated signaling networks in chemotherapy sensitive (CS) and resistant (CR) TNBC patient-derived xenografts (PDX), to gain novel therapeutic insights. The antitumor activity of SFK inhibition was examined in vivo. Treated tumors were further subjected to phosphoproteomic and RNAseq analysis, to identify the mechanism of actions of the drug. We identified Src Family Kinases (SFKs) as potential therapeutic targets in CR TNBC PDXs. Treatment with dasatinib, an FDA approved SFK inhibitor, led to inhibition of tumor growth in vivo. Further analysis of post-treatment PDXs revealed multiple mechanisms of actions of the drug, confirming the multi-target inhibition of dasatinib. Analysis of pTyr in tumor specimens suggested a low prevalence of SFK-driven tumors, which may provide insight into prior clinical trial results demonstrating a lack of dasatinib antitumor activity in unselected breast cancer patients. Taken together, these results underscore the importance of pTyr characterization of tumors, in identifying new targets, as well as stratifying patients based on their activated signaling networks for therapeutic options. Our data provide a strong rationale for studying SFK inhibitors in biomarker-selected SFK-driven TNBC.
Recurrent Stroke and Racial Disparities
O’Carroll, Cumara B. , Dumitrașcu, Oana

Mayo Clinic

Neurology | August 30, 2022 | Volume: 99 | Issue: 22 | Pages: 975-976

10.1212/wnl.0000000000201338 | PMID 36041867 Get It

Do Americans Lacking a Local Orthopaedic Surgeon Have Adequate Broadband for Telehealth?
Cwalina, Thomas B. , Schmidt, Jenna E. , Wu, Victoria S., Haglin, Jack M. , Jella, Tarun K. , Kamath, Atul F.

Mayo Clinic

Clinical Orthopaedics & Related Research | August 30, 2022 | Volume: 481 | Issue: 2 | Pages: 347-355

10.1097/corr.0000000000002374 | PMID 36040749 Get It

Abstract Background Although telehealth holds promise in expanding access to orthopaedic surgical care, high-speed internet connectivity remains a major limiting factor for many communities. Despite persistent federal efforts to study and address the health information technology needs of patients, there is limited information regarding the current high-speed internet landscape as it relates to access to orthopaedic surgical care. Questions/purposes (1) What is the distribution of practicing orthopaedic surgeons in the United States relative to the presence of broadband internet access? (2) What geographic, demographic, and socioeconomic factors are associated with the absence of high-speed internet and access to a local orthopaedic surgeon? Methods The Federal Communications Commission (FCC) Mapping Broadband in America interactive tool was used to determine the proportion of county residents with access to broadband-speed internet for all 3141 US counties. Data regarding the geographic distribution of orthopaedic surgeons and county-level characteristics were obtained from the 2015 Physician Compare National Downloadable File and the Area Health Resource File, respectively. The FCC mapping broadband public use files are considered the most comprehensive datasets describing high-speed internet infrastructure within the United States. The year 2015 represents the most recently available FCC data for which county-level broadband penetration estimates are available. Third-party audits of the FCC data have shown that broadband expansion has been slow over the past decade and that many large improvements have been driven by changes in the reporting methodology. Therefore, we believe the 2015 FCC data still hold relevance. The primary outcome measure was the simultaneous absence of at least 50% broadband penetration and at least one orthopaedic surgeon practicing in county limits. Statistical analyses using Kruskal-Wallis tests and multivariable logistic regression were conducted to assess for factors associated with inaccessibility to orthopaedic telehealth. All statistical tests were two-sided with a significance threshold of p < 0.05. Results In 2015, 14% (448 of 3141) of counties were considered “low access” in that they both had no orthopaedic surgeons and possessed less than 50% broadband access. A total of 4,660,559 people lived within these low-access counties, representing approximately 1.4% (4.6 million of 320.7 million) of the US population. After controlling for potential confounding variables, such as the age, sex, income level, and educational attainment, lower population density per square mile (OR 0.92 [95% confidence interval (CI) 0.90 to 0.94]; p < 0.01), a lower number of primary care physicians per 100,000 (OR 0.88 [95% CI 0.81 to 0.97]; p < 0.01), a higher unemployment level (OR 1.3 [95% CI 1.2 to 1.4]; p < 0.01), and greater number preventable hospital stays per 100,000 (OR 1.01 [95% CI 1.01 to 1.02]; p < 0.01) were associated with increased odds of being a low-access county (though the effect size of the finding was small for population density and number of primary care physicians). Stated another way, each additional person per square mile was associated with an 8% (95% CI 6% to 10%; p < 0.01) decrease in the odds of being a low-access county, and each additional percentage point of unemployment was associated with a 30% (95% CI 20% to 40%) increase in the odds of being a low-access county. Conclusion Despite the potential for telehealth programs to improve the delivery of high-quality orthopaedic surgical care, broadband internet access remains a major barrier to implementation. Until targeted investments are made to expand broadband infrastructure across the country, health systems, policymakers, and surgeon leaders must capitalize on existing federal subsidy programs, such as the lifeline or affordability connectivity initiatives, to reach unemployed patients living in economically depressed regions. The incorporation of internet access questions into clinic-based social determinants screening may facilitate the development of alternative follow-up protocols for patients unable to participate in synchronous videoconferencing. Clinical Relevance Some orthopaedic patients lack the broadband capacity necessary for telehealth visits, in which case surgeons may pursue alternative methods of follow-up such as mobile phone–based surveillance of postoperative wounds, surgical sites, and clinical symptoms.
SARS-CoV-2 With Concurrent Respiratory Viral Infection as a Risk Factor for a Higher Level of Care in Hospitalized Pediatric Patients
Dikranian, Lea , Barry, Suzanne, Ata, Ashar, Chiotos, Katie, Bhalala, Utpal , Danesh, Valerie , Heavner, Smitty, Irby, Olivia, Heneghan, Julia A. , Gupta, Neha , Miller, Aaron , Boman, Karen , Bansal, Vikas , Kumar, Vishakha K. , Sayed, Imran A., Woll, Christopher , Group, From the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: COVID-19 Registry Investigator, Kumar, Vishakha, Bansal, Vikas , Gist, Katja M. , Gharpure, Varsha , Bjornstad, Erica C. , Montgomery, Vicki , Walkey, Allan J. , Tripathi, Sandeep , Kashyap, Rahul , Group, From the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: COVID-19 Registry Investigator

Mayo Clinic

Pediatric Emergency Care | August 30, 2022 | Volume: 38 | Issue: 9 | Pages: 472-476

10.1097/pec.0000000000002814 | PMID 36040468 Get It

Objective As of early 2021, there have been over 3.5 million pediatric cases of SARS-CoV-2, including 292 pediatric deaths in the United States. Although most pediatric patients present with mild disease, they are still at risk for developing significant morbidity requiring hospitalization and intensive care unit (ICU) level of care. This study was performed to evaluate if the presence of concurrent respiratory viral infections in pediatric patients admitted to the hospital with SARS-CoV-2 was associated with an increased rate of ICU level of care. Design A multicenter, international, noninterventional, cross-sectional study using data provided through The Society of Critical Care Medicine Discovery Network Viral Infection and Respiratory Illness Universal Study database. Setting The medical ward and ICU of 67 participating hospitals. Patients Pediatric patients younger than 18 years hospitalized with SARS-CoV-2. Interventions None. Measurements and Main Results A total of 922 patients were included. Among these patients, 391 required ICU level care and 31 had concurrent non–SARS-CoV-2 viral coinfection. In a multivariate analysis, after accounting for age, positive blood culture, positive sputum culture, preexisting chronic medical conditions, the presence of a viral respiratory coinfection was associated with need for ICU care (odds ratio, 3.6; 95% confidence interval, 1.6–9.4; P < 0.01). Conclusions This study demonstrates an association between concurrent SARS-CoV-2 infection with viral respiratory coinfection and the need for ICU care. Further research is needed to identify other risk factors that can be used to derive and validate a risk-stratification tool for disease severity in pediatric patients with SARS-CoV-2.
Ovarian Signet-ring Stromal Tumor
Tchrakian, Naïri , Oliva, Esther , Rivera-Polo, Barbara, Nucci, Marisa R. , Sah, Shatrughan Prasad , Schoolmeester, J. Kenneth , Griend, Rachael van der , Young, Robert H. , McCluggage, W. Glenn , Chong, Anne‐Sophie , Bennett, Jennifer A. , Foulkes, William D. , Clarke, Blaise

Mayo Clinic

American Journal of Surgical Pathology | August 30, 2022 | Volume: 46 | Issue: 12 | Pages: 1599-1610

10.1097/pas.0000000000001954 | PMID 36040033 Get It

Signet-ring stromal tumor (SRST) is a rare ovarian stromal neoplasm characterized by a population of bland signet-ring cells, devoid of mucin or lipid, in a generally cellular fibromatous stroma. Previous reports have described heterogenous immunohistochemical and molecular genetic findings, including occasional nuclear β-catenin expression and/or CTNNB1 mutations. We report 10 ovarian stromal neoplasms originally diagnosed as SRST. All but 1 tumor underwent detailed immunohistochemical analysis (including β-catenin) and 5 of 10 had CTNNB1 mutation analysis performed. All tumors contained a population of morphologically bland signet-ring cells that ranged from 15% to 95% of the neoplasm, characterized by a single large empty intracytoplasmic vacuole, mostly with nuclear indentation. Six of the 10 tumors contained cellular fibroma-like areas, comprising from 10% to 85% of the neoplasm. Three of the 10 tumors were reclassified as microcystic stromal tumor with signet-ring cells on the basis of the microcyst formation and hyalinized stroma, beta-catenin and cyclin D1 nuclear expression and/or CTNNB1 mutation, CD10 staining and largely absent expression of inhibin and calretinin. In the remaining 7 tumors, the diagnosis of SRST remained, constituting the largest series of SRST reported in the literature to date. The results of our study suggest that a subset of tumors diagnosed as ovarian SRST, especially those which show β-catenin nuclear positivity and/or CTNNB1 mutation, likely represent microcystic stromal tumor with variant morphology. We also suggest that at least a subset of SRSTs without evidence of Wnt/β-catenin pathway abnormalities may be related to ovarian fibromas. We discuss the differential diagnosis of ovarian neoplasms containing signet-ring cells.
Clinical management of hypoactive sexual desire disorder in postmenopausal women
Kingsberg, Sheryl A. , Faubion, Stephanie S.

Mayo Clinic

Menopause | August 30, 2022 | Volume: 29 | Issue: 9 | Pages: 1083-1085

10.1097/gme.0000000000002049 | PMID 36040433 Get It

Approximately 10% to 12% of women meet the criteria for hypoactive sexual desire disorder, with the highest prevalence in midlife women, ranging from 14.5% to 33%. Despite the negative effect on health and quality of life, most women are reluctant to discuss sexual concerns with healthcare professionals. Although healthcare professionals have the best opportunities to address these problems, most of them have limited awareness, education, and comfort about addressing sexual concerns, resulting in a conspiracy of silence. The purpose of this Practice Pearl is to improve the understanding of hypoactive sexual desire disorder, including symptoms, etiology, diagnosis, and treatment.
Primary localized cutaneous amyloidosis of lower leg with 12 years follow‐up
Deo, Neha , Gibson, Lawrence E. , Johnson, Emma F. , Alavi, Afsáneh , Gibson, Lawrence, Johnson, E F , Alavi, A , Deo, Neha N

Mayo Clinic

International Journal of Dermatology | August 30, 2022 | Volume: 62 | Issue: 4 | Pages: No page available

10.1111/ijd.16404 | PMID 36040002 Get It

Sequenced treatment after regorafenib and survival in metastatic colorectal cancer: a qualitative clinical review
Babajanyan, Svetlana , Pollack, Megan , Castelo, Sarah, Kavati, Abhishek , Bekaii‐Saab, Tanios

Mayo Clinic

Colorectal Cancer | August 30, 2022 | Volume: 10 | Issue: 1 | Pages: No page available

10.2217/crc-2022-0006 Get It

Gadolinium-based contrast agents for imaging of the central nervous system: A multicenter European prospective study
Behzadi, Ashkan Heshmatzadeh , Heshmatzadeh Behzadi, Ashkan , McDonald, Jennifer , McDonald, Jennifer S.

Mayo Clinic

Medicine | August 30, 2022 | Volume: 101 | Issue: 34 | Pages: e30163

10.1097/md.0000000000030163 | PMID 36042629 Get It

Contrast-enhanced MR (CE-MR) imaging is required to improve lesion detection and characterization and to increase diagnostic confidence. This study aims to evaluate the safety, effectiveness, and usage patterns of recently introduced Clariscan TM (gadoterate meglumine) and other macrocyclic gadolinium-based contrast agents (GBCAs) used for magnetic resonance imaging (MRI) of the central nervous system (CNS). Data was obtained from a European multicenter, prospective, observational postmarketing study that included pediatric and adult patients undergoing contrast-enhanced MRI with a GBCA used in routine clinical practice. Safety data was collected by spontaneous patient adverse event (AE) reporting. Effectiveness was assessed via changes in radiological diagnosis, diagnostic confidence, and image quality. 766 patients with CNS-related indications were included from 8 centers across 5 European countries between December 2018 and November 2019. Clariscan (gadoterate meglumine) was used in 66% (503) of exams, Dotarem ® (gadoterate meglumine) in 20% (160), Gadovist ® (gadobutrol) in 13% (97), and ProHance ® (gadoteridol) in 1%. GBCA use increased the diagnostic confidence in 95% (724/766) of patients and a change in radiological diagnosis in 65% (501/766) of patients. The Clariscan-specific data revealed an increase in diagnostic confidence in 94% (472/503) of patients and resulted in a change in radiological diagnosis in 58% (293/503) of patients. Image quality was considered excellent or good in 95% of patients across all GBCAs and in 94% of patients who received Clariscan. No AEs were reported in this cohort including Clariscan. This data demonstrates the excellent safety and efficacy profile of Clariscan and other GBCAs used in MRI examination of the CNS.
Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration
Lohse, Christine M. , Castillo, Anna , Tosakulwong, Nirubol , Lesnick, Timothy G. , Petersen, Ronald C. , Ruddy, Kathryn J. , Kantarci, Kejal , Kara, Firat , Castillo, Anna M, Ruddy, Kathryn J , Mielke, Michelle M , Kantarci, Kejal , Castillo, Anna M , Jack, Clifford R. , Olson, Janet E. , Couch, Fergus J. , Mielke, Michelle M.

Mayo Clinic

Cancer Medicine | August 30, 2022 | Volume: 12 | Issue: 3 | Pages: 2805-2817

10.1002/cam4.5175 | PMID 36040183 Get It

Abstract The aim of this cross‐sectional study was to examine whether a history of selective estrogen receptor modifiers (SERMs), tamoxifen and raloxifene, use was associated with cognitive performance, odds of mild cognitive impairment (MCI), or magnetic resonance imaging (MRI) markers of neurodegeneration associated with Alzheimer's disease. We included women with prior history of breast cancer or no prior history of any cancer at enrollment in the Mayo Clinic Study of Aging (MCSA). This information was abstracted using the Rochester Epidemiology Project medical‐linkage system. Logistic regression was used to examine associations of SERMs with odds of MCI. Linear regression models were used to examine associations of SERMs with cognitive z‐scores (Memory, Executive Function, Language, Visuospatial Skills, Global Cognition), and MRI markers. Among 2840 women aged 50 and older in the MCSA, 151 had a history of breast cancer, and 42 (28%) of these had a history of tamoxifen treatment. A total of 2235 women had no prior history of any cancer, and 76 (3%) of these had a history of raloxifene use. No significant associations between tamoxifen use and cognition, or odds of MCI were observed among women with a history of breast cancer after adjusting for confounders. Similarly, raloxifene use was not significantly associated with cognition, or odds of MCI in women without a history of cancer after adjusting for confounders. We did not find significant associations between the use of either SERM and MRI markers. Use of tamoxifen or raloxifene was not significantly associated with cognition in postmenopausal women.